Advertisement
Advertisement
MLTX
MoonLake Immunotherapeutics - Class A
52.08
USD+0.2
+0.39%
Dec 20, 15:59 UTC -5
Closed
...
MoonLake Immunotherapeutics - Class A Profile
About
Info & Links
CEO
Jorge Santos da Silva
Headquarters
ZUG, V8 6300, SWITZERLAND
Industry
Sector
Website
Auditor
Baker Tilly US, LLP
Share holders
9
Employees
50
MoonLake Immunotherapeutics - Class A Statistics
Valuation Measures
Market Capitalization2
3.54B
Enterprise Value
3.17B
Enterprise Value/EBITDA(ttm)
-29.22
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
6.69
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
-15.54%
Return on Invested Capital(ttm)
-16.03%
Return on Assets(ttm)
-15.09%
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-108.45M
Net Income Available to Common(ttm)
-80.77M
Diluted EPS(ttm)
-1.29
Share Statistics
Beta (5Y Monthly)
1.31
52-Week Change
10.27%
S&P 500 52-Week Change
24.74%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
63.91M
Dividend Yield
0.00%
Float4
56.22M
% Held by Insiders
12.02%
% Held by Institutions
93.85%
Balance Sheet
Total Cash(mrq)
493.92M
Total Cash Per Share(mrq)
7.73
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
25.51%
Quick Ratio(mrq)
25.51%
Book Value Per Share(mrq)
7.76
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.08
Free Cash Flow(ytd)
-68.46M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement